Research on inhibition of human gastric cancer SGC-7901 cells and drug-resistance in vitro by Diosbulbin B

doi:10.3969/j.issn.1674-490X.2014.03.002

Abstract

Abstract: Objective To research the inhibition of human gastric cancer SGC-7901 cells and drug-resistance cell strain in vitro by Diosbulbin B. Methods Induce human gastric cancer cell line SGC-7901 by drug concentration incremental method and set up its drug-resistance cell line of cis-platinum, 5-FU and adriamycin amycin respectively. Test the proliferation inhibition ratio of Diosbulbin B to SGC-7901, SGC-7901/cis-platinum SGC-7901/5-FU and SGC-7901/adriamycin amycin applying MTT method, at the meantime,compare the proliferation inhibition ratio between SGC-7901 and its drug-resistance cell strain. Results Diosbulbin B showed an effect of concentration dependent anti-proliferation within the scope of certainly concentration range to human gastric cancer cell line SGC-7901, SGC-7901/cis-platinum, SGC-7901/5-FU and SGC-7901/adriamycin (P<0.05), meanwhile, Diosbulbin B showed same effect within the scope of certainly concentration range to cis-platinum, 5-FU and adriamycin amycin drug-resistance cell strain of human gastric cancer cell line SGC-7901 (P>0.05). Conclusion Diosbulbin B show low cross resistance on the human gastric cancer cell line SGC-7901, and develop the same affect of proliferation inhibition when the cell line multidrug resistance with cis-platinum, 5-FU and adriamycin amycin.

Key words: Diosbulbin B, human gastric cancer SGC-7901 cells, drug-resistance cell strain, cross resistance, anti tumor activity in vitro

CLC Number:

R285.5

LIU Bo,CHENG Shujie. Research on inhibition of human gastric cancer SGC-7901 cells and drug-resistance in vitro by Diosbulbin B[J]. Medical Reserch and Education, 2014, 31(3): 6-10.

References

[1] Ling Yang. Incidence and mortality of gastric cancer in China [J]. 世界胃肠病学杂志（英文版） 2006.
[2] 谭兴起, 阮金兰, 陈海生, 王菊英, 王杰松. 黄药子抗炎活性成分的研究 [J]. 第二军医大学学报 2003.doi:10.3321/j.issn:0258-879X.2003.06.030
[3] 李国进. 黄药子在治疗亚急性甲状腺炎中的作用 [J]. 天津中医药 2003.doi:10.3969/j.issn.1672-1519.2003.02.049
[4] 索晴, 崔立然, 刘树民, 杨婷婷, 刘学伟. 黄药子及配伍当归后含药血清抗肿瘤作用的研究 [J]. 中国中医药科技 2008.doi:10.3969/j.issn.1005-7072.2008.02.016
[5] 喻泽兰, 刘欣荣, Michael McCulloch, 高锦. 黄药子抗肿瘤活性组分筛选及作用分析 [J]. 中国中药杂志 2004.doi:10.3321/j.issn:1001-5302.2004.06.021
[6] 赵继森, 程树杰, 李鹏凯, ZHAO Jisen, CHENG Shujie, LI Pengkai. 黄独乙素抑制人胃癌SGC－7901细胞增殖作用 [J]. 医学研究与教育 2013.
[7] 程樱, 张立. 中药抗肿瘤机制及药物研究进展 [J]. 中国药业 2013.
[8] 吕贺, LV He. 中药抗肿瘤机制的研究现状 [J]. 医学综述 2011.doi:10.3969/j.issn.1006-2084.2011.19.042
[9] 李庆, 范晓磊. 中药抗肿瘤的研究进展 [J]. 中国微生态学杂志 2007.doi:10.3969/j.issn.1005-376X.2007.03.039
[10] 廖美德, 梁世中. 中药抗肿瘤机理的研究进展 [J]. 贵阳中医学院学报 2001.doi:10.3969/j.issn.1002-1108.2001.04.045
[11] 季秀海, 钱晓萍, 刘宝瑞, JI Xiu-hai, QIAN Xiao-ping, LIU Bao-rui. 中药有效成分抗肿瘤血管生成研究进展 [J]. 现代肿瘤医学 2010.doi:10.3969/j.issn.1672-4992.2010.03.069
[12] 李春峰, 邱军强, 苗晶囡, 张翀, 张宁, 刘树民. 黄药子体外抗胃癌活性成分的筛选及分析 [J]. 中成药 2014.doi:10.3969/j.issn.1001-1528.2014.02.039
[13] 李俊萱, 于海食, 宋雨婷, 贾强华. 黄药子的现代研究进展 [J]. 中国医药指南 2013.
[14] 江苏中医学院. 中药大辞典(下册) [M]. 上海:上海科学技术出版社 1977.
[15] Yang L. Incidence and mortality of gastric cancer in China. [J]. World Journal of Gastroenterology 2006, 1(1).
[16] 翟为民, 张力, ZHAI Weimin, ZHANG Li. 黄药子的安全性评价与风险控制措施探讨 [J]. 中国中药杂志 2010.doi:10.4268/cjcmm20101731
[17] 李学涛, 谭静净, 喻荣平, 贾天柱. 中药逆转抗肿瘤药物多药耐药性研究进展 [J]. 2013.
[18] 赵许杰, 闫雪生, 孙丹丹, ZHAO Xu-jie, YAN Xue-sheng, SUN Dan-dan. 黄药子的药理作用和临床研究进展 [J]. 药物评价研究 2012.
[19] 陈云龙, 吴勉华. 中医药逆转肿瘤多药耐药研究现状及局限性分析 [J]. 2014.
[20] 王洁茹, 张婷婷, 程晓东. 中药抗卵巢癌侵袭转移及化疗耐药的研究 [J]. 实用肿瘤杂志 2014.